Anthera Pharmaceuticals (ANTH) Stock Price, Quote, News and Overview
NASDAQ:ANTH - Nasdaq -
ANTH Quote, Performance and Key Statistics
0.117
-0.15 (-56.67%)
The current stock price of ANTH is 0.117 null. In the past month the price decreased by -46.82%. In the past year, price decreased by -92.78%.
About ANTH
Company Profile
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj'gren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
Company Info
Anthera Pharmaceuticals
25801 INDUSTRIAL BOULEVARD SUITE B
HAYWARD CA 94545
CEO: J. Craig Thompson
Phone: 510-856-5600
Anthera Pharmaceuticals / ANTH FAQ
What is the stock price of Anthera Pharmaceuticals today?
The current stock price of ANTH is 0.117 null. The price decreased by -56.67% in the last trading session.
What is the ticker symbol for Anthera Pharmaceuticals stock?
The exchange symbol of Anthera Pharmaceuticals is ANTH and it is listed on the Nasdaq exchange.
On which exchange is ANTH stock listed?
ANTH stock is listed on the Nasdaq exchange.
What is Anthera Pharmaceuticals worth?
Anthera Pharmaceuticals (ANTH) has a market capitalization of 3.06M null. This makes ANTH a Nano Cap stock.
Should I buy Anthera Pharmaceuticals (ANTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANTH, evaluating the profitability, health, valuation and growth aspects
- Anthera Pharmaceuticals (ANTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Anthera Pharmaceuticals (ANTH) Sales and EPS estimates to see what analysts future expectations are.
- Anthera Pharmaceuticals (ANTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Anthera Pharmaceuticals (ANTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- Anthera Pharmaceuticals (ANTH) Stock Chart to make your own analysis
- Anthera Pharmaceuticals (ANTH) Latest news and press-releases to stay up to date.
Does Anthera Pharmaceuticals (ANTH) stock pay dividends?
ANTH does not pay a dividend.
What is the Price/Earnings (PE) ratio of Anthera Pharmaceuticals (ANTH)?
Anthera Pharmaceuticals (ANTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.59).
What is the Short Interest ratio of Anthera Pharmaceuticals (ANTH) stock?
The outstanding short interest for Anthera Pharmaceuticals (ANTH) is 0.01% of its float. Check the ownership tab for more information on the ANTH short interest.
ANTH Technical Analysis
ANTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANTH. Both the profitability and financial health of ANTH have multiple concerns.
ANTH Financial Highlights
Over the last trailing twelve months ANTH reported a non-GAAP Earnings per Share(EPS) of -2.59. The EPS increased by 70.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -265.47% | ||
| ROE | -428.33% | ||
| Debt/Equity | 0 |